The effect of the in vitro addition of colchicine on various aspects of leukocyte metabolism was investigated. Colchicine in 6 mm concentration reduced the oxygen uptake of phagocytizing leukocytes to below the level of resting cells. A similar concentration of colchicine inhibited the increase in glucose-1-'4C oxidation by 90% and the quantitative nitroblue tetrazolium reduction by about 50%. Experiments with broken cell preparations indicate that the inhibition of the hexose monophosphate shunt is due to an inhibition of the activity of the shunt enzymes glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase. In spite of these pronounced metabolic changes, the addition of 6 mm colchicine had no observable effect on the bactericidal activity of the leukocyte against three test organisms. These results support a mechanism for phagocytosis in which the hexose monophosphate-shunt activation is a secondary phenomenon which is not required for the actual killing process.
Our interest in the biochemical concomitants of the phagocytic process was stimulated by the discovery of a patient with a total deficiency of leukocyte glucose-6-phosphate dehydrogenase activity (5) . The phagocytes of this patient showed normal ingestion of bacteria, but there was no increase in hexose monophosphate-shunt (HMS) activity upon ingestion. Further, the HMS could not be stimulated by the addition of methylene blue to the white cells of the patient, in contrast to the situation described in chronic granulomatous disease of children (3) . Other enzyme activities including reduced nicotinamide adenine dinucleotide (NADH) oxidase, reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, and myeloperoxidase were normal in this patient. The clinical picture of the patient was characterized by recurrent infections, and in vitro tests demonstrated an impaired bactericidal activity toward catalase-positive bacteria.
The exact relationship of an activated HMS to the bactericidal activity of the leukocyte is unclear, although most workers feel that the shunt increase is a secondary phenomenon dependent upon the generation of H202 by the cell (1, 22) . However, the defect in leukocyte glucose-6-phosphate dehydrogenase activity associated with decreased bacterial killing might imply a closer relationship between the shunt and killing process. This would agree with a recent hypothesis of Schlegel and Bellanti (23) which implies that a deficiency of leukocyte glucose-6-phosphate dehydrogenase is responsible for the increased susceptibility of male infants to infection.
The present study was designed to clarify the relationship between the HMS and the bactericidal activity of the leukocyte. Goldfinger et al. (6) showed that the drug colchicine would inhibit the oxidation of glucose-1-'4C by human leukocytes. Malawista and Bodel (16) further demonstrated that colchicine could inhibit the increase in oxygen consumption that normally accompanies phagocytosis, without significantly affecting the ingestion of bacteria by the leukocyte.
The results presented here indicate that the mechanism of the colchicine inhibition of glucose-1-14C oxidation involves inhibition of the shunt enzymes glucose-6-phosphate dehydrogenase and 6-phosphogluconic acid dehydrogenase. Further (4) with the following modifications. (i) Phosphate-buffered saline containing 200 mg of glucose per 100 ml was substituted for the KrebsHenseleit buffer; (ii) two sets of phagocytizing tubes were run, one containing 0.10 ml of latex spherules and one containing 0.25 ml; and (iii) colchicine was added to some tubes, whereas an equal volume of water was added to others. Preliminary experiments indicated that the quantities of colchicine used did not interfere with the absorbance due to reduced nitroblue tetrazolium dye.
Phagocytic and bactericidal activities. Phagocytic and bactericidal activities were determined with modifications of the Maal0e technique (15), utilizing stock strains of Escherichia coli, Staphylococcus albus, and Serratia marcescens. An 18-hr culture in broth was centrifuged, washed once, and suspended in saline to a standardized optical density (0.08 at 620 nm) in a Coleman Jr. spectrophotometer. The bacterial suspension was added to a suspension of phagocytes (neutrophils, eosinophils, and monocytes) in a ratio of approximately 10 bacteria to 1 phagocyte. A final concentration of 10% fresh serum obtained from normal volunteers was employed in samples. Each assay included: (i) control tubes of bacteria in Earle's medium 199 without phagocytes, (ii) phagocytes and bacteria without colchicine, and (iii) phagocytes and bacteria with a final concentration of 6 mm colchicine. The effects of 6 mm colchicine alone upon the individual bacteria were determined. Colchicine had no bactericidal activity against any of the test organisms.
The total number of viable bacteria was enumerated by plate dilution at the beginning of incubation and, after 60 to 120 min of end-over-end rotation, by transferring samples to distilled water for cell lysis and 10-fold dilutions. Leukocyte-associated bacteria were also determined after 60 and 120 min by separating the sediment by centrifugation at 800 X g for 5 min, lysing the cells in distilled water, and counting the bacteria as a measure of leukocyte-associated bactericidal activity. All tests were done in duplicate. Leukocyte Enzyme activities. The activities of leukocyte glucose-6-phosphate dehydrogenase and 6-phosphogluconic acid dehydrogenase in the presence of various amounts of colchicine were measured spectrophotometrically as previously described (11, 13 colchicine has no effect on the oxygen consumption of phagocytizing leukocytes.
Because the nitroblue tetrazolium test has been used by some workers as an indication of NADH oxidase activity (4, 18) , the effect of colchicine on this test was observed. Table 3 demonstrates that a colchicine concentration of 6 mm inhibits the reduction of nitroblue tetrazolium by about 50 to 60% in either resting or phagocytizing cells.
Control experiments, in which the colchicine was added after the reaction was terminated, demonstrated that the drug did not interfere with the absorbance of the reduced dye. When colchicine was added in a concentration of 1 mm, there was no appreciable effect on the nitroblue tetrazolium dye reduction (data not shown).
To explain the inhibition of HMS by colchicine, the in vitro effects of the drug on a number of leukocyte enzyme activities were measured. Figure  1 illustrates the effect of various concentrations of colchicine on the activity of leukocyte glucose-6-phosphate dehydrogenase. A Tables 4 and 5 show that colchicine has no effect on the total clearance of bacteria or upon intracellular bactericidal activity of the leukocyte toward three difference test organisms at 60 and 120 min. The presence of 6 mm colchicine in the medium does not alter the total clearance of bacteria (Table 4) , and it does not increase the number of viable leukocyte-associated bacteria (Table 5 ). Because of the relatively low number of bacteria associated with the leukocyte, there is a considerable variation in the number of colonies. However, in those examples with the most marked variation, i.e., S. marcescens at 60 min, there were fewer leukocyte-associated bacteria in the flask containing colchicine than in the control.
Viability tests were performed to ascertain whether colchicine might be adversely affecting the leukocytes. After (16) who found that low concentrations of colchicine will inhibit the increase in oxygen consumption that normally accompanies phagocytosis. They further observed that the addition of relatively large amounts of colchicine (2.5 X 10-4 M) had no effect on phagocytosis when measured at 20, 40, and 60 min. This lack of effect on phagocytosis confirms a report by Penny et al. (20) who observed that, although colchicine did not affect phagocytosis, it did decrease the adhesiveness of neutrophils.
Phelps (21) has recently demonstrated that colchicine inhibits the release of a chemotactic substance from the leukocytes. Wallace et al. (26) have studied the plasma levels of colchicine in patients and concluded that the only physiologically significant effect is on the migration of leukocytes toward a chemotactic source. Reports in the literature on the effects of colchicine on bacterial killing by leukocytes are fragmentary and contradictory. Holmes et al. (8) cite unpublished data of Kaplan, Quie, and Windhorst which claims that colchicine-treated neutrophils will phagocytize bacteria normally but will show a bacterial killing defect similar to that seen in cells from chronic granulomatous patients. Lehrer and Cline (14) reported that colchicine (10-4 M) inhibits the candidacidal activity of normal neutrophils to about 57% of control. Because of the lack of precision inherent in killing studies, this figure is of questionable significance. Malawista and Bodel (16) , on the other hand, reported that concentrations of colchicine as high as 2.5 X 10-4 M had no effect on the killing of an alpha-hemolytic streptococcus by leukocytes. However, since this organism is catalase-negative and thought to produce its own hydrogen peroxide (17) , it is a relatively poor choice as a test organism.
The present results confirm earlier reports that colchicine will inhibit the increase in oxygen uptake and glucose-1-'4C oxidation normally observed with phagocytosis. This study further demonstrates that colchicine will interfere with the nitroblue tetrazolium reduction test, although this inhibition is not so pronounced as the first two noted.
A possible mechanism for the colchicine inhibition of the HMS is indicated by the observations that colchicine added in vitro to a sonic extract of leukocytes is a potent inhibitor of the shunt enzymes glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase.
The observation that higher levels of colchicine are needed to inhibit oxygen uptake and the HMS than to inhibit the enzymes in vitro is probably related to permeability of the cells to the drug.
In spite of these diverse effects of colchicine on leukocyte metabolism, the present study could show no significant effect on the ingestion and bactericidal activities of the leukocyte. Levels of colchicine which strongly inhibited both oxygen uptake and HMS activity did not interfere to any detectable degree with the ability of the white cell to kill three species of bacteria. None of the three bacteria tested, E. coli, S. albus, and S. marcescens, produces its own hydrogen peroxide (17) This mechanism is supported by Baehner and Karnovsky (2) who have described a defect in NADH oxidase which results in defective bacterial killing. This defect, however, has been questioned by another laboratory (8) .
A second scheme, which has been suggested by Strauss et al. (24) (12, 25) . There is some controversy as to whether the peroxidation of reduced glutathione is an enzymatic reaction. Baehner and Karnovsky (1) have been unable to identify a glutathione peroxidase in human white cells but report that the reaction occurs spontaneously. Holmes et al. (9) , on the other hand, not only have reported the presence of enzyme activity but have described two patients with a deficiency of the enzyme. This disparity remains to be resolved.
A major difference between the two schemes lies in the role of the HMS. In the first mechanism, the activation of the HMS is a secondary event which occurs after the generation of hydrogen peroxide. However, in the second mechanism, the activation of the shunt occurs early in the sequence of reactions and the formation of hydrogen peroxide is secondary to the shunt increase. The second hypothesis has been favored by Holmes et al. (9) as a means of explaining the bactericidal defect in patients with a deficiency of leukocyte glutathione peroxidase. It is also compatible with the data of Bellanti et al. (23) who postulates a defect in glucose-6-phosphate dehydrogenase activity in the leukocytes of children with chronic granulomatous disease. This postulate was attractive to us because it supplied a ready explanation for the defective bactericidal activity of the leukocytes from our patient with a total deficiency of leukocyte glucose-6-phosphate dehydrogenase (5 
